Upexi, Inc.: Form 10-Q/A for the period ended Mar 31, 2023
Filed with the SEC on May 19, 2023 and accepted by EDGAR at May 19, 2023, 21:20 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $24.2m | us-gaap:Revenues |
| Revenue | 9 months2022-07-01 to 2023-03-31 | $62.9m | us-gaap:Revenues |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $14.6m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2022-07-01 to 2023-03-31 | $36.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-01-01 to 2023-03-31 | $9.6m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-07-01 to 2023-03-31 | $26.0m | us-gaap:GrossProfit |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$2.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-07-01 to 2023-03-31 | −$7.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-01-01 to 2023-03-31 | −$496.9k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-07-01 to 2023-03-31 | −$449.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$1.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-07-01 to 2023-03-31 | $1.6m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-07-01 to 2023-03-31 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-07-01 to 2023-03-31 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 18,015,837 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-07-01 to 2023-03-31 | 17,418,877 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-07-01 to 2023-03-31 | $3.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-07-01 to 2023-03-31 | $278.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-03-31 | $1.2m | us-gaap:Cash |
| Current assets | At period end2023-03-31 | $20.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $73.8m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $17.7m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2023-03-31 | $37.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001477932-23-003802. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.